Hormonal
One year after TORe, patients experience a significant overall decrease in postprandial Glucagon-like peptide-1 (GLP-1) levels, regardless of the specific technique used (APC vs. suture) or clinical success status.
After TORe, your levels of GLP-1 (a hormone that helps regulate blood sugar and satiety) tend to drop significantly one year later. Despite this drop, patients often still see improvements in blood sugar and lipids. This suggests that weight loss and other factors are more important for metabolic health than GLP-1 levels alone.
Our study demonstrated that 1 year after TORe, patients experienced an overall decrease in GLP-1 levels. This finding was constant, regardless of allocation group, CS, or history of cholecystectomy.
Why this rating
Statistically significant decrease, but the clinical implication (worsening metabolic parameters vs. actual improvement) is unclear.
Source
Endoscopic transoral outlet reduction induces enterohormonal changes in patients with weight regain after Roux-en-Y gastric bypass
Vitor Brunaldi et al. · Endoscopy International Open · 2024
DOI 10.1055/a-2312-5742
More from this paper
- Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.Moderate
- Transoral outlet reduction (TORe) delays the postprandial decrease in ghrelin levels by approximately 30 minutes, shifting the nadir from 30 minutes to 60-90 minutes, without significantly altering the total ghrelin exposure (AUC) or correlating with clinical success.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →